Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Long-Term Investments (2018 - 2023)

Arrowhead Pharmaceuticals (ARWR) has disclosed Long-Term Investments for 12 consecutive years, with $42.8 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Long-Term Investments fell 74.2% year-over-year to $42.8 million, compared with a TTM value of $42.8 million through Jun 2023, down 74.2%, and an annual FY2022 reading of $105.9 million, down 56.89% over the prior year.
  • Long-Term Investments was $42.8 million for Q2 2023 at Arrowhead Pharmaceuticals, down from $78.8 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $245.6 million in Q3 2021 and bottomed at $26.3 million in Q4 2019.
  • Average Long-Term Investments over 5 years is $122.9 million, with a median of $113.4 million recorded in 2020.
  • The sharpest move saw Long-Term Investments soared 321.67% in 2020, then tumbled 74.2% in 2023.
  • Year by year, Long-Term Investments stood at $26.3 million in 2019, then skyrocketed by 321.67% to $110.9 million in 2020, then soared by 96.19% to $217.6 million in 2021, then tumbled by 46.78% to $115.8 million in 2022, then plummeted by 63.04% to $42.8 million in 2023.
  • Business Quant data shows Long-Term Investments for ARWR at $42.8 million in Q2 2023, $78.8 million in Q1 2023, and $115.8 million in Q4 2022.